60 degrees pharmaceuticals announces communication from the fda of intention to respond to tafenoquine-babesiosis trial protocol submission in april, 2024

60 degrees pharma advises of expected fda response a month later than anticipated. prepares for june 1, 2024, start of trial of tafenoquine for babesiosis.
SXTP Ratings Summary
SXTP Quant Ranking